GC
RYTM icon

Guggenheim Capital’s Rhythm Pharmaceuticals RYTM Stock Holding History

Guggenheim Capital’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.22M Sell
10,984
-5,570
-34% -$504K 0.01% 939
2026
Q1 		$1.44M Buy
16,554
+4,153
+33% +$404K 0.01% 836
2025
Q4 		$1.33M Buy
12,401
+10,116
+443% +$1.07M 0.01% 802
2025
Q3 		$231K Buy
+2,285
New +$212K ﹤0.01% 1479

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Guggenheim Capital's RYTM Position: Q2 2026 in Review

Guggenheim Capital reduced its Rhythm Pharmaceuticals (RYTM) stake by 34% in Q2 2026, selling an estimated $504K and leaving 10,984 shares worth $1.22M. The position accounts for 0.01% of the portfolio, ranked #939.

Guggenheim Capital first reported a position in RYTM in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.44M in Q1 2026. 305 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Guggenheim Capital held 10,984 shares of Rhythm Pharmaceuticals worth $1.22M as of Q2 2026.
  • Guggenheim Capital sold 5,570 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $504K.
  • Rhythm Pharmaceuticals made up 0.01% of Guggenheim Capital's portfolio in Q2 2026, its #939 holding.
  • Guggenheim Capital first reported a position in Rhythm Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Guggenheim Capital's Rhythm Pharmaceuticals position peaked at $1.44M in Q1 2026.
  • 305 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.